In malignant pleural mesothelioma, EZH2 inhibition activates monocyte differentiation into the TAM phenotype, further promoting mesenchymal stem cell growth and extracellular matrix remodeling, which contributes to high invasion rates and poor survival [152]. This evidence concerns the gene EZH2 and malignant pleural mesothelioma.